Axsome Therapeutics (AXSM) Stock Forecast & Price Target

$97.19 +2.59 (+2.74%)

(As of 01:28 PM ET)

Axsome Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 14 Analyst Ratings

Sell
0

Hold
0

Buy
14

Based on 14 Wall Street analysts who have issued ratings for Axsome Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 14 analysts, 14 have given a buy rating for AXSM.

Consensus Price Target

$124.93
28.54% Upside

According to the 14 analysts' twelve-month price targets for Axsome Therapeutics, the average price target is $124.93. The highest price target for AXSM is $180.00, while the lowest price target for AXSM is $105.00. The average price target represents a forecasted upside of 28.54% from the current price of $97.19.

Get the Latest News and Ratings for AXSM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Axsome Therapeutics and its competitors.

AXSM Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	14 Buy rating(s)	14 Buy rating(s)	13 Buy rating(s)	8 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$124.93	$124.64	$123.38	$103.22
Forecasted Upside	28.54% Upside	34.90% Upside	40.23% Upside	71.75% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

Trump won. Buy this coin now. (Ad)

Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

This could be his favorite coin.

AXSM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AXSM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Axsome Therapeutics Stock vs. The Competition

Type	Axsome Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	32.06% Upside	26,931.60% Upside	9.83% Upside
News Sentiment Rating	Positive News See Recent AXSM News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/13/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$112.00 ➝ $116.00	+16.59%
11/12/2024	Needham & Company LLC 3 of 5 stars	A. Fadia Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$130.00 ➝ $130.00	+42.89%
10/4/2024	Royal Bank of Canada 4 of 5 stars		Boost Target	Outperform ➝ Outperform	$130.00 ➝ $131.00	+48.46%
9/16/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight ➝ Overweight	$107.00 ➝ $107.00	+13.93%
9/5/2024	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$180.00 ➝ $180.00	+88.36%
9/3/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Chen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$140.00	+57.55%
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad) It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development… YES, I WANT THE #1 CRYPTO NOW
8/6/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$107.00 ➝ $105.00	+22.39%
8/6/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$95.00 ➝ $106.00	+27.39%
6/12/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$106.00 ➝ $106.00	+49.15%
5/7/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$127.00 ➝ $125.00	+65.87%
4/29/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Equal Weight ➝ Overweight	$90.00 ➝ $115.00	+60.37%
3/26/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$150.00	+91.30%
2/21/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$110.00 ➝ $125.00	+54.02%
1/16/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$90.00 ➝ $113.00	+32.40%
8/7/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
6/22/2023	VNET Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Reiterates
12/23/2022	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$62.00 ➝ $98.00	+30.44%
11/29/2022	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Outperform	$65.00 ➝ $85.00	+13.73%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:44 PM ET.

AXSM Forecast - Frequently Asked Questions

: According to the research reports of 14 Wall Street equities research analysts, the average twelve-month stock price forecast for Axsome Therapeutics is $124.93, with a high forecast of $180.00 and a low forecast of $105.00.
: 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AXSM shares.
: According to analysts, Axsome Therapeutics's stock has a predicted upside of 28.54% based on their 12-month stock forecasts.
: Axsome Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, Robert W. Baird, Royal Bank of Canada, and Wells Fargo & Company in the past 90 days.
: Analysts like Axsome Therapeutics more than other "medical" companies. The consensus rating for Axsome Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AXSM compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NASDAQ:AXSM) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Stock Forecast & Price Target